Clinical Drug Investigation

, Volume 40, Issue 1, pp 83–92 | Cite as

Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease

  • Sheridan M. HoyEmail author
Adis Drug Evaluation


Collagenase Clostridium Histolyticum (hereafter referred to as CCH) [Xiaflex®; Xiapex®] is a mixture of two Clostridium histolyticum collagenases [AUX-I (a Class I clostridial collagenase) and AUX-II (a Class II clostridial collagenase)]. Administered by intralesional injection, it is available in various countries for the treatment of adult men with Peyronie’s disease (PD). In two double-blind, multinational, phase III studies, CCH improved the physical (penile curvature) and psychological (patient-reported bother) aspects of PD in adult men. Such beneficial effects were also seen in two open-label, multinational, phase III studies, with potential benefits for patients’ partners and maintained efficacy over up to 5 years additionally reported. Moreover, large real-world studies generally supported the therapeutic efficacy of CCH. CCH was generally well tolerated in these patient populations, with most treatment-related adverse events [TRAEs; most commonly penile haematoma (or ‘bruising’), pain and swelling] being mild or moderate in severity, not serious and resolving without intervention. Moreover, the use of CCH was not associated with penile length shortening. Current evidence indicates that CCH is an effective, generally well tolerated and, compared with surgery, minimally invasive option for the treatment of adult men with PD.



During the peer review process, the manufacturer of Collagenase Clostridium Histolyticum was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    American Urological Association. Peyronie’s disease: AUA guideline; 2015. Accessed 26 July 2019.
  2. 2.
    Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12(5):E197–209.CrossRefGoogle Scholar
  3. 3.
    European Medicines Agency. Xiapex (collagenase clostridium histolyticum): EU assessment report; 2014. Accessed 15 July 2019.
  4. 4.
    Margolin EJ, Pagano MJ, Aisen CM, et al. Beyond curvature: prevalence and characteristics of penile volume-loss deformities in men with Peyronie’s disease. Sex Med. 2018;6(4):309–15.CrossRefGoogle Scholar
  5. 5.
    Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115–8.CrossRefGoogle Scholar
  6. 6.
    Hatzimouratidis K, Giuliano F, Moncada I, et al. EAU guidelines on penile curvature; 2017. Accessed 26 July 2019.
  7. 7.
    Paulis G. Natural history of Peyronie’s disease. In: Cavallini G, Paulis G, editors. Peyronie’s disease: a comprehensive guide. Cham: Springer; 2015. p. 27–37.Google Scholar
  8. 8.
    Cwikla DJ, Yafi FA. Intralesional collagenase clostridium histolyticum in the management of Peyronie’s disease: current best practice. Ther Adv Urol. 2018;10(4):139–53.CrossRefGoogle Scholar
  9. 9.
    Swedish Orphan Biovitrum AB. Xiapex (collagenase clostridium histolyticum) 0.9 mg powder and solvent for solution for injection: EU summary of product characteristics; 2017. Accessed 6 June 2019.
  10. 10.
    Endo Pharmaceuticals Inc. XIAFLEX® (collagenase clostridium histolyticum) for injection, for intralesional use: US prescribing information; 2016. Accessed 6 June 2019.
  11. 11.
    Endo Ventures Ltd. XIAFLEX® (collagenase clostridium histolyticum) lyophilized powder for solution 0.9 mg/vial: Canadian product monograph; 2019. Accessed 30 July 2019.
  12. 12.
    Dhillon S. Collagenase clostridium histolyticum: a review in Peyronie’s disease. Drugs. 2015;75(12):1405–12.CrossRefGoogle Scholar
  13. 13.
    Dhillon S. Collagenase clostridium histolyticum in Peyronie’s disease: a guide to its use in the EU. Drugs Ther Perspect. 2016;32(8):311–6.CrossRefGoogle Scholar
  14. 14.
    Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207.CrossRefGoogle Scholar
  15. 15.
    Data on file, Endo Pharmaceuticals Inc.; 2013.Google Scholar
  16. 16.
    Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627–34.CrossRefGoogle Scholar
  17. 17.
    Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116(4):650–6.CrossRefGoogle Scholar
  18. 18.
    Kaminetsky J, Gittelman M, Kaufman GJ, et al. Patient perspectives on Peyronie’s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum. Int J Impot Res. 2018;31:263–8.CrossRefGoogle Scholar
  19. 19.
    Yule M, Davison J, Brotto L. The International Index of Erectile Function: a methodological critique and suggestions for improvement. J Sex Marital Ther. 2011;37(4):255–69.CrossRefGoogle Scholar
  20. 20.
    Hellstrom WJ, Feldman RA, Coyne KS, et al. Self-report and clinical response to Peyronie’s disease treatment: Peyronie’s disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies. Urology. 2015;86(2):291–8.CrossRefGoogle Scholar
  21. 21.
    Levine LA, Larsen SM. Surgical correction of persistent Peyronie’s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12(1):259–64.CrossRefGoogle Scholar
  22. 22.
    Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268–74.CrossRefGoogle Scholar
  23. 23.
    Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248–58.CrossRefGoogle Scholar
  24. 24.
    Goldstein I, Knoll LD, Lipshultz LI, et al. Changes in the effects of Peyronie’s disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. Sex Med. 2017;5(2):e124–30.CrossRefGoogle Scholar
  25. 25.
    Goldstein I. Long-term safety and curvature deformity characterization in patients previously treated with collagenase clostridium histolyticum for Peyronie’s disease [abstract no. 111]. J Sex Med. 2019;16(4 Suppl 1):S57.CrossRefGoogle Scholar
  26. 26.
    Goldstein I, Liu G, McLane M, et al. Impact of collagenase clostridium histolyticum treatment of men with Peyronie’s disease on improvement of female partner sexual function [abstract no. PD54-05]. J Urol. 2018;199(4 Suppl):e1053.Google Scholar
  27. 27.
    Ziegelmann MJ, Viers BR, McAlvany KL, et al. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195(4 Part 1):1051–6.CrossRefGoogle Scholar
  28. 28.
    Hellstrom WJG, Tue Nguyen HM, Alzweri L, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie’s disease: results of a multi-institutional analysis. J Urol. 2019;201(4):777–82.CrossRefGoogle Scholar
  29. 29.
    Nguyen HMT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med. 2017;14(10):1220–5.CrossRefGoogle Scholar
  30. 30.
    Wymer K, Ziegelmann M, Savage J, et al. Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie’s disease. Urology. 2018;119:109–14.CrossRefGoogle Scholar
  31. 31.
    DeLay K, Diao L, Nguyen HMT, et al. Successful treatment of residual curvature in Peyronie disease in men previously treated with intralesional collagenase clostridium histolyticum. Urology. 2017;110:110–3.CrossRefGoogle Scholar
  32. 32.
    Carson CC 3rd, Sadeghi-Nejad H, Tursi JP, et al. Analysis of the clinical safety of intralesional injection of collagenase clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int. 2015;116(5):815–22.CrossRefGoogle Scholar
  33. 33.
    Sun A, Li S, Eisenberg M. Corporal rupture and collagenase clostridium histolyticum: a population based study [abstract no. PD44-05]. J Urol. 2018;199(4 Suppl):e882–3.Google Scholar
  34. 34.
    Yafi FA, Anaissie J, Zurawin J, et al. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease. J Sex Med. 2016;13(4):684–9.CrossRefGoogle Scholar
  35. 35.
    Hellstrom WJ. Medical management of Peyronie’s disease. J Androl. 2009;30(4):397–405.CrossRefGoogle Scholar
  36. 36.
    Coyne KS, Currie BM, Thompson CL, et al. Responsiveness of the Peyronie’s Disease Questionnaire (PDQ). J Sex Med. 2015;12(4):1072–9.CrossRefGoogle Scholar
  37. 37.
    Anaissie J, Hellstrom WJ, Yafi FA. Collagenase clostridium histolyticum for the treatment of Peyronie’s disease: a ‘real world’ clinical perspective. Drugs. 2016;76(16):1523–8.CrossRefGoogle Scholar
  38. 38.
    Tsambarlis PN, Yong R, Levine LA. Limited success with collagenase clostridium histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res. 2019;31(1):15–9.CrossRefGoogle Scholar
  39. 39.
    Tal R. Editorial comment on ‘Limited success with collagenase clostridium histolyticum following FDA approval for the treatment of Peyronie’s disease’. Int J Impot Res. 2019;31(1):54–5.CrossRefGoogle Scholar
  40. 40.
    Masterson T, Patel P, Ramasamy R. RE: Limited success with collagenase clostridium histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res. 2019. Scholar
  41. 41.
    Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie’s disease in an era of effective clinical treatment. J Sex Med. 2019;16(9):1421–32.CrossRefGoogle Scholar
  42. 42.
    Cordon BH, Hofer MD, Hutchinson RC, et al. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie’s disease deformities. Urol Pract. 2017;4(2):118–25.CrossRefGoogle Scholar
  43. 43.
    Diao L, Anaissie J, Nguyen HMT, et al. Effect of collagenase clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie’s disease. Transl Androl Urol. 2017;6(5):894–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations